| 0 (0%) | 09-27 11:11 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 17.35 | 1-year : | 20.27 |
| Resists | First : | 14.85 | Second : | 17.35 |
| Pivot price | 12.42 |
|||
| Supports | First : | 12.68 |
Second : | 11.33 |
| MAs | MA(5) : | 13.42 |
MA(20) : | 12.45 |
| MA(100) : | 10.05 |
MA(250) : | 9.5 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 74  |
D(3) : | 76.2 |
| RSI | RSI(14): 64.3 |
|||
| 52-week | High : | 18.7 | Low : | 5 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ATRA ] has closed below upper band by 10.4%. Bollinger Bands are 38.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 14.04 - 14.12 | 14.12 - 14.18 |
| Low: | 12.77 - 12.86 | 12.86 - 12.94 |
| Close: | 13.6 - 13.74 | 13.74 - 13.86 |
Thu, 25 Sep 2025
Atara Biotherapeutics (ATRA) Soars 10.0%: Is Further Upside Left in the Stock? - Yahoo Finance
Tue, 23 Sep 2025
Airbus A320 ATRA Flies in IOC Configuration Ahead of Eurofighter’s AESA Radar Testing - The Aviationist
Tue, 23 Sep 2025
Atara Biotherapeutics (NASDAQ:ATRA) Share Price Passes Below 50-Day Moving Average - Should You Sell? - MarketBeat
Mon, 22 Sep 2025
State Tort Laws Negatively Impacting Economies Outlined for DOJ in ATRA Letter - Legal Reader
Mon, 08 Sep 2025
All-Trans Retinoic Acid and Arsenic Trioxide in High-Risk Acute Promyelocytic Leukemia - The ASCO Post
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 7 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 21.2 (%) |
| Held by Institutions | 45.6 (%) |
| Shares Short | 174 (K) |
| Shares Short P.Month | 211 (K) |
| EPS | 0.72 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -5.02 |
| Profit Margin | 3 % |
| Operating Margin | 26.8 % |
| Return on Assets (ttm) | 15.7 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -38.6 % |
| Gross Profit (p.s.) | 0.78 |
| Sales Per Share | 26.87 |
| EBITDA (p.s.) | 3.41 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -64 (M) |
| Levered Free Cash Flow | -64 (M) |
| PE Ratio | 19.08 |
| PEG Ratio | 0 |
| Price to Book value | -2.74 |
| Price to Sales | 0.51 |
| Price to Cash Flow | -1.51 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | 2024-11-23 |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|